Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
Key facts
- Where
- Aarhus N és Herlev, DániaSee the 2 sites
- Phase
- 2. fázis
Where in Dánia
- Aarhus University HospitalAarhus N, DániaTaking people
- Steno Diabetes Center CopenhagenHerlev, DániaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Steno Diabetes Center Copenhagen
- Trial code
- EU 2025-524679-22-00
- Record updated
- 2026. március 4.
- Original description
We aim to systematically assess the effects of up-titration of glimepiride on continuous glucose monitoring (CGM) metrics in individuals diagnosed with HNF1A- or HNF4A-MODY including those who have previously been treated as individuals with T1D or T2D.Read full original descriptionShow less
We aim to systematically assess the effects of up-titration of glimepiride on continuous glucose monitoring (CGM) metrics in individuals diagnosed with HNF1A- or HNF4A-MODY including those who have previously been treated as individuals with T1D or T2D.
Inclusion: HbA1c ≥48 mmol/mol and/or current insulin treatment; Age ≥18 years; Diabetes caused by a heterozygous mutation (pathogenic or likely pathogenic according to ACMG criteria) in the HNF1A-gene or HNF4A-gene; Informed consent.
Exclusion: Treatment with SU or glinides within the last 30 days; End-stage liver disease; Known allergic reaction to study drug (glimepiride or other sulphonamides); Nephropathy (eGFR <30 ml/min/1.73 m2 and/or persistent severely increased albuminuria (urine-albumin-creatinine ratio >300 mg/g)); Breastfeeding, pregnancy or inadequate contraceptive methods in women with childbearing potential; Contraindications for use of specific CGM device (e.g. non-manageable skin reactions, use of substances interfering with measurements etc.).